Single and sequential combination intravesical chemotherapy of murine bladder cancer

Mark S. Soloway, Israel Nissenkorn, Lee W. McCallum, William M. Murphy

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer. In the first experiment 106 C3H/He mice were divided into a control and three treatment groups. Therapy consisted of either cis-diamminedichloroplatinum (II) (DDP), mitomycin C, or thio-tepa. There was a reduction in the tumor incidence in all treated groups; this was statistically significant for those receiving mitomycin C (p < 0.04) and DDP (p < 0.001). No significant difference in the mean or median tumor weight (an index of tumor volume) between the treated and control groups was found. In a second experiment intravesical combination chemotherapy was compared to single-agent therapy. Animals received either doxorubicin hydrochloride (Adriamycin), mitomycin C, thio-tepa, mitomycin C + doxorubicin, or mitomycin C + thio-tepa. Although there was no significant difference in tumor incidence among the groups with the exception of mice receiving thio-tepa, animals receiving sequential combination chemotherapy had lower mean and median bladder weights suggesting an improved therapeutic effect.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalUrology
Volume19
Issue number2
DOIs
StatePublished - Jan 1 1982
Externally publishedYes

Fingerprint

Thiotepa
Mitomycin
Combination Drug Therapy
Urinary Bladder Neoplasms
Doxorubicin
Tumor Burden
FANFT
Neoplasms
Incidence
Inbred C3H Mouse
Therapeutic Uses
Cisplatin
Urinary Bladder
Therapeutics
Animal Models
Weights and Measures
Control Groups
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Urology

Cite this

Soloway, M. S., Nissenkorn, I., McCallum, L. W., & Murphy, W. M. (1982). Single and sequential combination intravesical chemotherapy of murine bladder cancer. Urology, 19(2), 169-175. https://doi.org/10.1016/0090-4295(82)90574-X

Single and sequential combination intravesical chemotherapy of murine bladder cancer. / Soloway, Mark S.; Nissenkorn, Israel; McCallum, Lee W.; Murphy, William M.

In: Urology, Vol. 19, No. 2, 01.01.1982, p. 169-175.

Research output: Contribution to journalArticle

Soloway, MS, Nissenkorn, I, McCallum, LW & Murphy, WM 1982, 'Single and sequential combination intravesical chemotherapy of murine bladder cancer', Urology, vol. 19, no. 2, pp. 169-175. https://doi.org/10.1016/0090-4295(82)90574-X
Soloway, Mark S. ; Nissenkorn, Israel ; McCallum, Lee W. ; Murphy, William M. / Single and sequential combination intravesical chemotherapy of murine bladder cancer. In: Urology. 1982 ; Vol. 19, No. 2. pp. 169-175.
@article{e52f17cdcbf34aeba4bcea855b7ca228,
title = "Single and sequential combination intravesical chemotherapy of murine bladder cancer",
abstract = "We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer. In the first experiment 106 C3H/He mice were divided into a control and three treatment groups. Therapy consisted of either cis-diamminedichloroplatinum (II) (DDP), mitomycin C, or thio-tepa. There was a reduction in the tumor incidence in all treated groups; this was statistically significant for those receiving mitomycin C (p < 0.04) and DDP (p < 0.001). No significant difference in the mean or median tumor weight (an index of tumor volume) between the treated and control groups was found. In a second experiment intravesical combination chemotherapy was compared to single-agent therapy. Animals received either doxorubicin hydrochloride (Adriamycin), mitomycin C, thio-tepa, mitomycin C + doxorubicin, or mitomycin C + thio-tepa. Although there was no significant difference in tumor incidence among the groups with the exception of mice receiving thio-tepa, animals receiving sequential combination chemotherapy had lower mean and median bladder weights suggesting an improved therapeutic effect.",
author = "Soloway, {Mark S.} and Israel Nissenkorn and McCallum, {Lee W.} and Murphy, {William M.}",
year = "1982",
month = "1",
day = "1",
doi = "10.1016/0090-4295(82)90574-X",
language = "English",
volume = "19",
pages = "169--175",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Single and sequential combination intravesical chemotherapy of murine bladder cancer

AU - Soloway, Mark S.

AU - Nissenkorn, Israel

AU - McCallum, Lee W.

AU - Murphy, William M.

PY - 1982/1/1

Y1 - 1982/1/1

N2 - We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer. In the first experiment 106 C3H/He mice were divided into a control and three treatment groups. Therapy consisted of either cis-diamminedichloroplatinum (II) (DDP), mitomycin C, or thio-tepa. There was a reduction in the tumor incidence in all treated groups; this was statistically significant for those receiving mitomycin C (p < 0.04) and DDP (p < 0.001). No significant difference in the mean or median tumor weight (an index of tumor volume) between the treated and control groups was found. In a second experiment intravesical combination chemotherapy was compared to single-agent therapy. Animals received either doxorubicin hydrochloride (Adriamycin), mitomycin C, thio-tepa, mitomycin C + doxorubicin, or mitomycin C + thio-tepa. Although there was no significant difference in tumor incidence among the groups with the exception of mice receiving thio-tepa, animals receiving sequential combination chemotherapy had lower mean and median bladder weights suggesting an improved therapeutic effect.

AB - We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer. In the first experiment 106 C3H/He mice were divided into a control and three treatment groups. Therapy consisted of either cis-diamminedichloroplatinum (II) (DDP), mitomycin C, or thio-tepa. There was a reduction in the tumor incidence in all treated groups; this was statistically significant for those receiving mitomycin C (p < 0.04) and DDP (p < 0.001). No significant difference in the mean or median tumor weight (an index of tumor volume) between the treated and control groups was found. In a second experiment intravesical combination chemotherapy was compared to single-agent therapy. Animals received either doxorubicin hydrochloride (Adriamycin), mitomycin C, thio-tepa, mitomycin C + doxorubicin, or mitomycin C + thio-tepa. Although there was no significant difference in tumor incidence among the groups with the exception of mice receiving thio-tepa, animals receiving sequential combination chemotherapy had lower mean and median bladder weights suggesting an improved therapeutic effect.

UR - http://www.scopus.com/inward/record.url?scp=0020078267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020078267&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(82)90574-X

DO - 10.1016/0090-4295(82)90574-X

M3 - Article

C2 - 6800090

AN - SCOPUS:0020078267

VL - 19

SP - 169

EP - 175

JO - Urology

JF - Urology

SN - 0090-4295

IS - 2

ER -